SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizer is trending following news of its acquisition of Metsera, a weight-loss drug developer, for a potential $7.3 billion. While some see this as a strategic move to enter the growing obesity market, others question the timing and price, noting the competitive landscape. The community is actively discussing the implications for Pfizer's pipeline, potential competition with other GLP-1 drugs, and whether this will finally boost the undervalued stock.

Bloom Energy Corp. engages in the manufacture and installation of a solid oxide fuel-cell based power generation platform. Its product, Bloom Energy Server, converts standard low-pressure natural gas or biogas into electricity through an electrochemical process without combustion. The company was founded by K. R. Sridhar, John Finn, Jim McElroy, Matthias Gottmann, and Dien Nguyen on January 18, 2001, and is headquartered in San Jose, CA.

Bloom Energy Corp - Ordinary Shares - Class A

Bloom Energy Corp

Bloom Energy ($BE) is trending due to growing optimism surrounding its role in powering AI data centers, with the community discussing the potential for significant growth and high price targets. A recent application for fuel cells to power a large power plant in Wyoming, along with comments from the Energy Secretary about hydrogen's role in powering the grid, are driving bullish sentiment. Community members are noting the stock's momentum and discussing potential short squeezes given the high short interest.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings is trending downwards, with community members discussing the impact of prediction markets and increased competition from platforms like Kalshi and Robinhood. Some traders are speculating about potential support levels and whether the company will adapt its strategy. Despite the bearish sentiment, some investors see the dip as a buying opportunity, citing the company's strong position in the sports betting sector.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is trending as the community rallies around its vision of linking crypto with cannabis culture, emphasizing freedom and growth within the digital space. Discussions highlight its potential as a culture coin, with community members sharing positive sentiments and links to purchase on Pump.fun and Dexscreener. The coin is also drawing attention for its association with the broader cannabis sector.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath is trending following news of partnerships with Nvidia, OpenAI, Snowflake, and Google, sparking discussions around its agentic automation platform and AI capabilities. The community is weighing the potential impact of these partnerships on UiPath's growth and market position, while also considering factors like high short interest and CEO stock sales. Investors are drawing comparisons to other AI-related stocks and debating whether this news could trigger a significant upward movement.

Draganfly, Inc. engages in the manufacture and sale of commercial unmanned aerial vehicle systems and software serving the public safety, agriculture, industrial inspections, security, mapping, and surveying markets. Its products include quad-copters, fixed wing aircrafts, ground based robots, hand held controllers, and software used for tracking, live streaming, and data collection. The firm also offers custom engineering, training, simulation consulting, as well as data and flight training services. The company was founded by Zenon Dragan and Christine Dragan in 1998 and is headquartered in Saskatoon, Canada.

Draganfly Inc

DPRO is trending due to news of the company being selected by the U.S. Army to supply drone systems, including manufacturing and training support at overseas facilities, though financial terms were not disclosed. The community is discussing the potential impact of this military contract, with some speculating about a possible short squeeze given the stock's high short interest. Bullish sentiment is fueled by the company's position in the growing drone warfare market, while others express concerns about potential offerings.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is trending amid discussions about upcoming earnings and a potential turnaround, with community members debating whether the stock can break out. Recent partnerships, such as the SKIMS collaboration, are generating buzz, while analysts weigh in on the impact of tariffs and competition. Some traders are also closely monitoring technical indicators and potential trading strategies around the stock.

PayPal Holdings, Inc. engages in the development of technology platforms that enable digital payments and simplifies commerce experiences on behalf of merchants and consumers worldwide. Its solutions include PayPal, PayPal Credit, Braintree, Venmo, Xoom, and Paydiant products. The firm also enables consumers to exchange funds with merchants using funding sources, which include bank account, PayPal account balance, PayPal Credit account, credit, and debit card or other stored value products. It operates through United States and Other Countries geographical segments. The company was founded in December 1998 and is headquartered in San Jose, CA.

PayPal Holdings Inc

PayPal is trending as the community discusses its potential following a partnership announcement, with some highlighting its undervalued status and strong buyback program. Despite positive news, skepticism remains around the stock's ability to sustain gains, with traders closely watching key resistance levels. Community members also point to buy-now-pay-later growth and potential partnerships.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Merck & Co Inc

MRK is trending as community members discuss the potential impact of new data and strategic partnerships in the pharmaceutical landscape. Discussions revolve around future growth opportunities amidst evolving market dynamics and Keytruda's patent expiration. Bullish sentiment is driven by potential pipeline developments, while bearish concerns stem from competitive pressures and broader industry trends.

HCM II Acquisition Corp. operates as a blank check company. It was formed for the purpose of entering into a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded on April 4, 2024 and is headquartered in Stamford, CT.

HCM II Acquisition Corp - Ordinary Shares - Class A

HCM II Acquisition Corp.

HCM II Acquisition Corp. ($HOND) is trending due to its upcoming merger with Terrestrial Energy and recent selection by the Department of Energy for its new reactor pilot program, generating excitement around its molten salt reactor technology. The community is comparing $HOND to other nuclear energy companies like $OKLO and speculating on its potential valuation post-merger, with some anticipating significant upside. Some users point to ZipTrader Charlie's coverage as a catalyst for increased interest.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of Immuneering Corp. rose 42% in after-hours trading on Wednesday after the company’s Phase 2a trial of atebimetinib in combination with modified gemcitabine/nab-paclitaxel showed an 86% overall survival rate in patients with first-line pancreatic cancer at nine months, compared with a 47% benchmark for standard of care.The stock closed Wednesday’s regular session up 7.5% at $9.23.Immuneering said it plans to seek regulatory feedback on its pivotal trial plans in the fourth quarter and, subject to that feedback, aims to launch a Phase 3 trial of atebimetinib plus mGnP by the end of 2025, with patient dosing to begin by mid-2026.&nbsp;The company also expects to initiate additional atebimetinib clinical trial combination arms in 2026, including in non-small cell lung cancer.Progression-free survival at nine months was 53%, compared to a 29% benchmark for standard of care. At six months, overall survival was 94%, and progression-free survival was 70%, both&nbsp;rates exceeding&nbsp;historical benchmarks. Median overall survival has not yet been reached.The treatment was generally well-tolerated. The serious side effects,&nbsp;observed in more than 1 in 10 people, included low white blood cell counts, which can increase the risk of infection, and anemia, characterized by low red blood cell levels. No new safety concerns were identified.CEO Ben Zeskind said the nine-month overall survival data widened the gap against&nbsp;the standard of care, describing the results as “extraordinary.” Chief Scientific Officer Brett Hall said atebimetinib, designed as a Deep Cyclic Inhibitor, represents a “fundamental shift in targeted therapy.”&nbsp;Vincent Chung, principal investigator of the trial at City of Hope, said the results mark “an important step” toward urgently needed new treatment options for pancreatic cancer, adding that the company is also planning a confirmatory study.&nbsp;Separately, Immuneering announced a proposed underwritten public offering of its Class A common stock, or in lieu of stock, pre-funded warrants. The company also stated that Sanofi agreed to purchase $25 million of shares in a concurrent private placement at the public offering price, with both transactions expected to close simultaneously.&nbsp;Immuneering plans to use the proceeds to advance the development of its drug candidates and for general corporate purposes.On Stocktwits, retail sentiment for Immuneering was ‘extremely bullish’ amid a 3,540% surge in 24-hour message volume, placing it among the top 10 trending equities on the platform.&nbsp;One user said the offering “didn’t completely kill the momentum,” adding that it gave them hope for the next trading day.&nbsp;<stembedurl>https://stocktwits.com/Mushichka/message/629894873</stembedurl>Another user said they were in “for the long haul, which now extends into mid-2026,” and added that the stock offering would likely be shrugged off within a day before analysts begin calculating Immuneering’s valuation based on potential sales of what they described as the gold standard for treating pancreatic cancer.<stembedurl>https://stocktwits.com/OptimistJP/message/629894127</stembedurl><a href="https://stocktwits.com/symbol/IMRX">Immuneering’s stock</a> has surged 320% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Immuneering’s stock (IMRX) has surged 320% so far in 2025. (Photo credit: Getty Images)

Why Immuneering Stock Soared Over 40% After-Hours Today

Updated trial data showed its drug atebimetinib nearly doubled survival benchmarks in first-line pancreatic cancer, with the company planning a pivotal Phase 3 study by late 2025.

Equity

Immuneering Stock Rises 21.7% on Supply Agreement With LLY

IMRX jumps 21.7% after striking a supply deal with Eli Lilly to test atebimetinib with the latter's olomorasib in non-small cell lung cancer.

Immuneering Corporation (IMRX) on Monday announced a clinical supply agreement with Eli Lilly and Company (LLY) for the latter’s investigational cancer drug Olomorasib.Immuneering <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/08/25/3138395/0/en/Immuneering-Announces-Clinical-Supply-Agreement-with-Lilly-to-Evaluate-Atebimetinib-in-Combination-with-Olomorasib.html">said</a> that the company would test its lead product candidate Atebimetinib, in combination with Olomorasib, in a planned mid-stage clinical trial in patients with a type of non-small cell lung cancer (NSCLC) who have progressed on prior therapy.In February, Immuneering announced a similar clinical trial agreement with Regeneron Pharmaceuticals to evaluate Atebimetinib in combination with Libtayo in patients with advanced non-small cell lung cancer.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/IMRX">IMRX stock</a> trended within ‘bullish’ territory over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels. IMRX stock traded 15% higher at the time of writing.<figure class="image"><img style="aspect-ratio:623/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_25_at_12_21_56_PM_png_6149d7e374.webp" alt="IMRX's Sentiment Meter and Message Volume as of 12:25 p.m. ET on Aug. 25, 2025 | Source: Stocktwits" width="623" height="61"><figcaption>IMRX's Sentiment Meter and Message Volume as of 12:25 p.m. ET on Aug. 25, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user said that they will buy more on dips.<stembedurl>https://stocktwits.com/BiotechBonesaw/message/626436428</stembedurl>Another user praised the company saying it has excellent products and good management.<stembedurl>https://stocktwits.com/OptimistJP/message/626406127</stembedurl>Chief Medical Officer of Immuneering Igor Matushansky said that the combination of the company’s drug with Lilly’s has the potential for enhanced tumor regression, delayed emergence of tumor resistance, and prolonged survival relative to monotherapy.&nbsp;&nbsp;&nbsp;&nbsp;“This dual-targeted approach has the potential to improve outcomes in a population with limited effective treatment options,” Matushansky added. Immuneering further said that it will maintain global development and commercialization rights to its drug Atebimetinib.IMRX stock is up by 156% this year and by about 381% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-exec-hints-at-possible-price-hike-on-model-y-in-us/chsssVVRdSR">Tesla Executive Hints At Possible Price Hike On Model Y In US: Retail Highlights Negative Catalysts</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Rising stock market chart on a trading board background.

Immuneering Inks Supply Agreement With Eli Lilly For Latter’s Investigational Cancer Therapy: Retail Looks To Buy The Stock On Dips

Immuneering said that the company would test its lead product candidate Atebimetinib, in combination with Olomorasib, in a planned mid-stage clinical trial in patients with a type of non-small cell lung cancer who have progressed on prior therapy.

Shares&nbsp;of Immuneering Corp saw increased retail chatter on Tuesday after the company reported positive interim results from its Phase 2a trial of atebimetinib in combination with modified gemcitabine/nab-paclitaxel (mGnP) in first-line pancreatic cancer.The stock&nbsp;initially surged on the news during morning trade&nbsp;but closed down 23.2% at $1.82 on Tuesday and slipped another 2.2% to $1.78 in after-hours trading.Trading activity likely indicated profit-taking, as Immuneering’s stock has gained more than 25% over the past month.The data demonstrated an overall survival (OS) rate of 94% and a progression-free survival (PFS) rate of 72% at 6 months among 34 patients who received atebimetinib at 320 mg once daily plus modified mGnP.&nbsp;Median OS and PFS had not yet been reached.&nbsp;The benchmark 6-month OS and PFS rates for&nbsp;the current standard-of-care treatment in this population are 67% and 44%, respectively.The overall response rate stood at 39%, with disease control seen in 81% of patients.&nbsp;Investigators noted durable tumor regressions, with multiple lesions reportedly rendered undetectable.&nbsp;No Grade 3 or higher adverse events were observed across most categories typically linked to standard chemotherapy regimens.The data prompted Immuneering to increase the trial’s target enrollment to 50 patients.&nbsp;A pivotal, randomized trial is planned for 2026, pending regulatory feedback later this year.Immuneering said additional Phase 2a data and regulatory milestones are expected in Q4 2025.On Stocktwits, retail sentiment was ‘extremely bullish’ amid ‘extremely high’ message volume.One user noted that the stock has never undergone a reverse split and suggested it has multiple upside targets, even speculating on potential buyout interest.&nbsp;<stembedurl>https://stocktwits.com/sam92/message/618211510</stembedurl>Another long-time holder said belief in the stock remains strong.<stembedurl>https://stocktwits.com/Starkravingmad/message/618210680</stembedurl>The stock has declined 17.7% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Illustration depicting tumour infiltrating lymphocyte (TIL) therapy for cancer treatment. During TIL therapy, T-cells (blue) that recognise tumour cells (red) are obtained from a patient. | Image source: Getty Images

Immuneering’s Positive Pancreatic Cancer Trial Data Sparks Bullish Retail Sentiment Even As Profit-Taking Cools Rally

The company plans to launch a pivotal trial in 2026 and expects additional clinical data and regulatory feedback by the end of 2025. 

U.S. biotech stocks, particularly small and mid-cap companies, remained a focal point for retail investors in 2024 despite significant volatility.&nbsp;Collectively, biotech stocks on U.S. bourses have garnered over 3.3 million watchers on Stocktwits.&nbsp;Here are the top five biotech stocks that saw the most significant surge in new followers this year:CERo Therapeutics Holdings Inc. (CERO): +44544% WatchersThis immunotherapy company develops engineered T-cell therapeutics for cancer. <a href="https://stocktwits.com/symbol/CERO">CERO</a> saw major retail interest following the FDA’s clearance of its lead compound, CER-1236, for Phase 1 clinical trials after an earlier clinical hold. The company went public via a SPAC merger in February and has lost 99% of its value this year.Psyence Biomedical Ltd. (PBM): +6741% WatchersKnown for developing natural psilocybin products for treating psychological trauma, PBM gained attention for positive results from its Phase IIb trial in adjustment disorder treatment for terminal cancer patients.&nbsp;Its&nbsp;shares have also dropped 99% this year since the company’s March SPAC debut.Azitra Inc. (AZTR): +2365% WatchersSpecializing in dermatological therapies using engineered proteins and live biotherapeutic products, AZTR drew attention for securing&nbsp;a fast track designation for ATR-04 and other multiple&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-are-azitra-shares-trending-on-wednesday/c7r4UW0RbE">patents</a>. Its stock value has plunged more than 99% since its debut in June last year.Immuneering Corporation (IMRX): +2248% WatchersFocused on oncology, IMRX’s lead program, IMM-1-104, received FDA orphan drug designation for pancreatic cancer and fast-track status to treat certain melanoma patients, and is currently in a Phase 2a trial. <a href="https://stocktwits.com/symbol/IMRX">IMRX shares</a> have declined over 70% year-to-date.NKGen Biotech Inc. (NKGN): +1260% WatchersNKGN develops autologous and CAR-NK cell therapies. Its SNK01 natural killer cell therapy for Alzheimer’s disease showed promising results, with 90% of patients maintaining or improving cognitive function. The candidate was cleared to progress into phase 2 clinical development, which will involve a larger group of 30 patients with moderate Alzheimer's disease. Shares, however, have fallen more than 66% this year.Despite their stock price struggles, these companies have captivated retail investors with groundbreaking therapies and promising clinical developments, positioning them as key biotech names to watch heading into 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Woman examining laboratory samples - stock photo | Image source: Getty Images

Top 5 Biotech Stocks That Captured Retail Investor Interest The Most In 2024

Despite their stock price struggles, these companies have captivated retail investors with groundbreaking therapies and promising clinical developments.

How Cutting-Edge Immunotherapies Are Redefining Cancer Treatment Options

How Cutting-Edge Immunotherapies Are Redefining Cancer Treatment Options How Cutting-Edge Immunotherapies Are Redefining Cancer Treatment Options PR Newswire VANCOUVER, BC, Dec. 23, 2024 Issued on...

Why Is Nanocap Immuneering Stock Trading Higher On Friday?

Immuneering reported promising initial response data from its Phase 2a trial for IMM-1-104 combined with modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer, showing a 40% response...

Early Detection Breakthrough: Biotech Companies Lead the Way in Pancreatic Cancer Treatment

Early Detection Breakthrough: Biotech Companies Lead the Way in Pancreatic Cancer Treatment Early Detection Breakthrough: Biotech Companies Lead the Way in Pancreatic Cancer Treatment PR Newswire...

Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conference

CAMBRIDGE, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for...

Immuneering price target lowered by $12 at Mizuho, here's why

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Immuneering Corp. operates as a clinical-stage oncology company, which engages in developing medicines for cancer patients. Its pipeline of drug candidates focuses on treating aspects of disease that have eluded conventional approaches, including cancer cachexia and metastasis. The company was founded by Robert J. Carpenter and Benjamin J. Zeskind in 2008 and is headquartered in Cambridge, MA.

Immuneering Corp - Ordinary Shares Class A

0 to 25,000

25,000 to 50,000

50,000 to 75,000

75,000 to 100,000

How many jobs did the U.S. add in September? Vote below + drop your exact prediction in the comments. 
 
*Powered by Polymarket

IMRX
Immuneering Corp

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest IMRX News

IMRX Immuneering Corp